Investigational drug · Phase 2
AVZO-021
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AVZO-021"
First trial start
2023
Aug 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AVZO-021", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR+/HER2- Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
- Advanced Solid Tumor
- CCNE1 Amplification
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- TNBC - Triple-Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AVZO-021" as an intervention, largest first.
Avenzo Therapeutics, Inc.Industry
NCT05867251 · 430 participants (planned) · Start Aug 30, 2023 · Primary completion Jan 31, 2028
Drug: AVZO-021; Palbociclib and 6 more · For: Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer and 6 more
Sites: New Haven, Connecticut; Sarasota, Florida; Tampa, Florida · 13 sites in all
Avenzo Therapeutics, Inc.Industry
NCT06998407 · 380 participants (planned) · Start Aug 20, 2025 · Primary completion Aug 2028
Drug: AVZO-021; Fulvestrant and 2 more · For: HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer
Sites: Los Angeles, California; New Haven, Connecticut; Orlando, Florida · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HR+/HER2- Breast Cancer
- BGB-43395Phase 31 trial
BeOne Medicines (BeiGene) · HR+/HER2- Breast Cancer
- AVZO-023Phase 21 trial
Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.